Tempus AI Expands Its AI Diagnostics Business – the Stock Starts the Big-Picture Breakout!
Reading Time: 2 minutes
Tempus AI (TEM) is regarded as a specialist in AI-driven precision medicine, conducting analyses based on an extensive database of over 350 petabytes of health data. There are over 4,500 integrations and 40 million connected patient records to support better treatment decisions and drug research with improved AI models. Starting from genomic testing, data licensing, and AI diagnostic tools in oncology, the offering is being expanded to neurology, cardiology, and radiology to capture a market worth around $200 billion. Tempus aims to develop...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
